# Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture

> **NCT04432389** · PHASE2 · UNKNOWN · sponsor: **Bone Therapeutics S.A** · enrollment: 178 (estimated)

## Conditions studied

- Tibial Fracture

## Interventions

- **BIOLOGICAL:** ALLOB
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04432389
- **Lead sponsor:** Bone Therapeutics S.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-08
- **Primary completion:** 2022-07-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2021-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04432389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04432389, "Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04432389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*